XASX
ADR
Market cap3mUSD
Sep 09, Last price
0.10AUD
Name
Adherium Ltd
Chart & performance
P/E
—
P/S
2.56
EPS
—
Vol. 1Y
—
Shs. 5Y
139.37%
Rev. 5Y
39.26%
Div Yld LY
—
Div Yld TTM
—
Revenues
2m
+157.02%
Net income
-14m
L+11.69%
CFO
-15m
L+48.58%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Adherium Limited specializes in developing, manufacturing, and providing advanced digital health solutions. The company's core mission is to enhance medication adherence for individuals managing chronic conditions in key international markets, spanning New Zealand, Australia, Europe, North America, and Asia. A central offering is Hailie, a comprehensive system engineered to optimize medication use for patients suffering from chronic respiratory illnesses like asthma and chronic obstructive pulmonary disease (COPD). This innovative solution integrates Bluetooth-enabled Hailie sensors, which discreetly attach to patients' inhalers to deliver immediate feedback. The Hailie ecosystem is further supported by an intuitive mobile application and a dedicated online portal. Established in 2001, Adherium Limited is headquartered in Auckland, New Zealand.
Key people
Executive Chairman of the Board · since 2024
Geoff Feakes
Chief Technology Officer · since 2020
Tara Creaven-capasso
Vice President - Quality, Regulatory and Clinical Affairs · since 2022
Timothy Houchin
Vice President - Sales · since 2018
Francis White
Vice President - Global Business Development · since 2022
Vik Panda
Vice President of Marketing · since 2017
Julia Chambers
Head of Corporate Development · since 2016
Nigel Devine
Head of Manufacturing - Consultant
Jane Lapon
Head of Global Market Access and Reimbursement · since 2020
Head of Commercial Development and Corporate Affairs · since 2016
Chris Mander
Head of Regulatory and Quality Affairs
Maggie Scott
Head of Clinical Operations
Emily Austin
Company Secretary · since 2024
George Baran
Non-Executive Director · since 2021
Jeremy Curnock-Cook
Non-Executive Director · since 2020
Keven Gessner
Non-Executive Director · since 2025
Bruce McHarrie
Non-Executive Independent Director · since 2015
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||